These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 12181048)

  • 21. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
    Rooney CM; Roskrow MA; Suzuki N; Ng CY; Brenner MK; Heslop H
    Ann Oncol; 1998; 9 Suppl 5():S129-32. PubMed ID: 9926252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for Epstein-Barr virus-associated cancers.
    Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
    J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus and Hodgkin's lymphoma.
    Andersson J
    Herpes; 2006 May; 13(1):12-6. PubMed ID: 16732997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
    Kohrt H; Johannsen A; Hoppe R; Horning SJ; Rosenberg SA; Advani R; Lee PP
    Oncol Res; 2009; 18(5-6):287-92. PubMed ID: 20225766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
    Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
    Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AIDS-related lymphoma in Brazil. Histopathology, immunophenotype, and association with Epstein-Barr virus.
    Bacchi CE; Bacchi MM; Rabenhorst SH; Soares FA; Fonseca LE; Barbosa HS; Weiss LM; Gown AM
    Am J Clin Pathol; 1996 Feb; 105(2):230-7. PubMed ID: 8607450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.
    Haque T; Taylor C; Wilkie GM; Murad P; Amlot PL; Beath S; McKiernan PJ; Crawford DH
    Transplantation; 2001 Oct; 72(8):1399-402. PubMed ID: 11685111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for EBV-associated malignancies.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Rosato A
    Int J Hematol; 2011 Mar; 93(3):281-293. PubMed ID: 21336546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
    Prockop S; Doubrovina E; Suser S; Heller G; Barker J; Dahi P; Perales MA; Papadopoulos E; Sauter C; Castro-Malaspina H; Boulad F; Curran KJ; Giralt S; Gyurkocza B; Hsu KC; Jakubowski A; Hanash AM; Kernan NA; Kobos R; Koehne G; Landau H; Ponce D; Spitzer B; Young JW; Behr G; Dunphy M; Haque S; Teruya-Feldstein J; Arcila M; Moung C; Hsu S; Hasan A; O'Reilly RJ
    J Clin Invest; 2020 Feb; 130(2):733-747. PubMed ID: 31689242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
    Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
    Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Heslop HE; Rooney CM
    Immunol Rev; 1997 Jun; 157():217-22. PubMed ID: 9255632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.
    Savoldo B; Heslop HE; Rooney CM
    Leuk Lymphoma; 2000 Nov; 39(5-6):455-64. PubMed ID: 11342329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
    Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
    Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
    Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
    Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma.
    Kersten MJ; Klein MR; Holwerda AM; Miedema F; van Oers MH
    J Clin Invest; 1997 Apr; 99(7):1525-33. PubMed ID: 9119996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.
    Gallot G; Vollant S; Saïagh S; Clémenceau B; Vivien R; Cerato E; Bignon JD; Ferrand C; Jaccard A; Vigouroux S; Choquet S; Dalle JH; Frachon I; Bruno B; Mothy M; Mechinaud F; Leblond V; Milpied N; Vié H
    J Immunother; 2014 Apr; 37(3):170-9. PubMed ID: 24598452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.